Last reviewed 2026-04-20 · How we verify

AC-701 Topical Gel 0.3%

TWi Biotechnology, Inc. · Phase 2 active Small molecule Quality 0/100

AC-701 Topical Gel 0.3% is a Small molecule drug developed by TWi Biotechnology, Inc.. It is currently in Phase 2 development. Also known as: AC-701.

At a glance

Generic name	AC-701 Topical Gel 0.3%
Also known as	AC-701
Sponsor	TWi Biotechnology, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AC-701 Topical Gel 0.3% CI brief — competitive landscape report
AC-701 Topical Gel 0.3% updates RSS · CI watch RSS
TWi Biotechnology, Inc. portfolio CI

Frequently asked questions about AC-701 Topical Gel 0.3%

What is AC-701 Topical Gel 0.3%?

AC-701 Topical Gel 0.3% is a Small molecule drug developed by TWi Biotechnology, Inc..

Who makes AC-701 Topical Gel 0.3%?

AC-701 Topical Gel 0.3% is developed by TWi Biotechnology, Inc. (see full TWi Biotechnology, Inc. pipeline at /company/twi-biotechnology-inc).

Is AC-701 Topical Gel 0.3% also known as anything else?

AC-701 Topical Gel 0.3% is also known as AC-701.

What development phase is AC-701 Topical Gel 0.3% in?

AC-701 Topical Gel 0.3% is in Phase 2.

Manufacturer: TWi Biotechnology, Inc. — full pipeline
Also known as: AC-701